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Schizophrenia patients are characterized by severe social impairments. Recently, social
cognition has been put forward as an important mediator in schizophrenia between the
often-reported neurocognitive deficits and functional outcome and is thus an important
target for treatments. Nicotine has been reported to improve neurocognitive processes
in schizophrenia patients but no studies have investigated possible nicotine-induced
facilitation of social cognition. The current placebo-controlled crossover study aimed
at bridging this gap by investigating whether the administration of active (1mg or
2mg) or placebo oromucosal nicotine spray resulted in improved social decision-making
in non-smoking (N = 15) and smoking (N = 16) schizophrenia patients. All patients
played the role of responder in a variant of the ultimatum game that allowed detailed
measurements of fairness and intentionality considerations. The results showed impaired
social decision-making in the non-smoking patients under placebo, but not in the smoking
patients. Interestingly, this impairment normalized after administration of 1mg of nicotine,
but not after 2mg of nicotine. Nicotine had no effect on performance in the smoking
patients. The present study indicates that nicotine improves social decision-making in
non-smoking patients. The present results suggest that acute nicotine effects may result
in a facilitation of proactive control through improved attentional processes. However,
the efficacy seems limited and although nicotine may thus be an interesting target for
(social) cognitive enhancement in the subset of patients that do not smoke, more research
is needed on the long-lasting effects of nicotine-based treatments.
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INTRODUCTION
Schizophrenia is a debilitating disorder, accompanied by severe
impairments ranging from delusions and hallucinations to disor-
ganized thinking, mood disturbances, and cognitive dysfunctions
(Burton, 2006). In line with the evident problems in social behav-
ior, more recent studies have demonstrated that patients with
schizophrenia are also impaired in a wide range of social cogni-
tive abilities, including emotion recognition (e.g., Kohler et al.,
2010), mentalizing (e.g., Sprong et al., 2007; Harvey et al., 2013),
and social decision-making (Csukly et al., 2011; Wischniewski
and Brune, 2011). Cognitive dysfunctions, such as poor work-
ing memory performance, are known to be good predictors of
functional outcome (Green et al., 2004). Interestingly, however, a
recent meta analysis provided evidence for an important mediat-
ing role of social cognition in between neurocognitive deficits and
functional outcome (Schmidt et al., 2011).
Since social cognitive deficits have tremendous effects on
patients’ wellbeing, their quality of life, as well as on functional
outcome, there is an urgent need for methods to improve these
processes in schizophrenia. One of the candidate components for
cognitive enhancement is nicotine as both smoking and nicotine
administration have been reported to improve sensory and atten-
tional processes in humans (for a recent review see Heishman
et al., 2010). In line with this, a growing number of studies have
demonstrated nicotine to enhance neurocognitive processes in
schizophrenia, such as sustained attention, anti-saccade perfor-
mance, or delayed recognition (see e.g., Depatie et al., 2002;Myers
et al., 2004; Barr et al., 2008). To this date, however, no one has
investigated the effects of nicotine on social cognitive functioning
in schizophrenia.
The aim of the present study is to bridge this gap by investi-
gating effects of acute nicotine administration on social decision-
making using a task derived from economic game theory in
both non-smoking and smoking patients with schizophrenia. The
main advantage of using economic games in studying social cog-
nition is that they allow for the investigation of more real-life
interpersonal interactions as compared to, for example, passive
emotion-recognition paradigms. An often-used economic game
is the so-called ultimatum game (UG; Güth et al., 1982) in which
two players have to decide how to split a certain amount ofmoney.
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One person proposes a split and the other person decides whether
to accept or reject the offer. When the second person accepts the
offer, the money is split as proposed, but when the decision is to
reject both players receive nothing. Variations of the game allow
for detailed measurements of processes such as fairness consid-
erations, intentionality, and perspective taking (Falk et al., 2003).
By limiting the number of offers the proposer can select from on
each trial to two, one can systematically study the influence of the
unchosen alternative on the decision-making process. Previous
studies using this variant of the UG have demonstrated that unfair
offers, for example, are more often rejected when they are paired
with a fair alternative, thus demonstrating that humans incorpo-
rate fairness considerations. On the other hand, when an unfair is
offer is paired with a similar and thus equally unfair offer, rejec-
tion rates decrease. Participants understand that in these cases
the proposer had no choice and did thus not select the unfair
offer intentionally. This latter process requires taking the perspec-
tive of the other into account and developmental studies using
this variant of the game have shown for example, that the pro-
cess of perspective taking is not fully developed until the age of
12 (Gürog˘lu et al., 2009). Studies using the UG have recently
demonstrated deviant behavioral strategies and impaired social
decision-making in schizophrenia patients (Csukly et al., 2011;
Wischniewski and Brune, 2011).
Because of the previously demonstrated positive effects of
nicotine on neurocognitive functioning, acute nicotine adminis-
tration is expected to facilitate social decision-making in patients
with schizophrenia. This hypothesis is supported by a recent
meta-analysis by Ventura et al. (2013) demonstrating a close
relationship between neurocognition and social-cognitive per-
formance. Neurocognitive processes such as working memory,
speed of processing, and attention showed moderate and rela-
tively consistent relationships with the social-cognitive processes
of emotion perception, social perception, and theory of mind. In
line with this, a recent study by Fanning et al. (2012) revealed that
normal range neurocognition is necessary, but not sufficient, for
good social performance. It is expected that under the influence of
nicotine, integration of different sources of information, such as
fairness and intentionality should be enhanced. Recent research
has demonstrated different nicotine-induced cortical excitabil-
ity patterns between chronic and acute use in humans (Grundey
et al., 2013). These differences in excitability may explain why
Newhouse et al. (2011) reported task-related activity increases
in non-smokers but not active smokers. Based on these recent
findings, the enhancement was especially expected for the non-
smoking patients with schizophrenia.
MATERIAL AND METHODS
PARTICIPANTS
Two patient groups (16 smoking and 16 non-smoking patients
with schizophrenia) were initially included in the study. One
patient of the non-smoking group did not perform the task
on one of the testing days and was therefore excluded from all
analyses. Demographic and clinical characteristics of the final
two groups are shown in Table 1. All patients were recruited
from the Psychiatric hospital Sint-Norbertushuis in Duffel and
the Psychiatric Hospital Stuivenberg in Antwerp, Belgium. All
Table 1 | Demographic variables of smoking and non-smoking
schizophrenic participants.
Smoking Non-smoking Significance
(n = 16) (n = 15) level of test*
Age (years) 32.6 (8.8) 40.1 (9.7) 0.031
Sex (M/F) 15/1 9/6 0.054
Education (years) 13.4 (2.3) 12.3 (2.6) 0.188
Chlorpromazine
equivalent
403.9 (271.9) 303.8 (207.4) 0.261
Equivalent for males only 417.5 (192.2) 402.4 (275.8) 0.887
Equivalent for females
only
200.0 (−) 155.8 (132.5) –
Total PANSS score 61.4 (9.5)ˆ 57.1 (9.4) 0.226
PANSS negative
symptoms
16.8 (5.3)ˆ 13.6 (2.9) 0.066
PANSS positive
symptoms
12.7 (3.0)ˆ 11.6 (3.1) 0.216
Cigarettes/day 24.6 (5.8) / /
Standard deviations are presented in parentheses.
*T-test for parametric data, Mann-Whitney test for non-parametric data.
ˆPANSS scores were available for 15 patients in the Smoking group.
patients received some form of psychotherapy, such as cognitive-
behavioral therapy. Importantly, none of the patients received
specific social-cognitive therapy or social skills training. Of the
final 15 participants in the non-smoking group, 11 patients were
outpatients. In the smoking group, 9 of the 16 patients were
outpatients. The study was carried out in correspondence with
the latest version of the Helsinki Declaration and was approved
by the medical–ethical committees of the participating hospitals.
All participants gave their written informed consent. The study
was performed according to Good Clinical Practice (GCP) and
approved by BelgianHealth Authority (HA). The clinicaltrials.gov
identifier of this study is NCT01186471 and the EudraCT number
is 2009-010616-14.
Smoking patients have been smoking at least 15 cigarettes/day
for a minimum of 3 years. Any smoking cessation agent, such
as nicotine replacement therapy, varenicline, or bupropion was
not allowed during the period of the study. Non-smoking partici-
pants were excluded if they used cigarettes or other nicotine-based
products within 3 months prior to the first experimental ses-
sion. All patients were prescribed a stable dose of antipsychotic
medication for at least two months prior to study assessments.
Patients taking anti-depressive or mood-stabilizing medication in
the two weeks prior to inclusion or anti-cholinergics two months
prior to the first experimental session were excluded. One non-
smoking patient taking a stable dose of a benzodiazepine for
sleeping (lormetazepam 2mg) was included in the experiment.
Patients with a DSM-IV axis I diagnosis other than schizophre-
nia that had been the focus of treatment or cause of disability
in the last 6 months, were excluded. Also, substance abuse or
dependence (e.g., cannabis, alcohol) other than nicotine was an
exclusion criterion for all participants. Finally, participants with
a history of or current significant medical disease were excluded
as well.
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Screening examination consisted of laboratory (serology,
hematology, chemistry, toxicology, urinalysis, and serum preg-
nancy test for women of childbearing potential), ECG and clinical
investigations by the research physician. Any clinical significant
deviation in these assessments was an exclusion criterion.
DESIGN
The study was a double-blind placebo-controlled randomized
three-way crossover design where participants received active
(1mg or 2mg) or placebo oromucosal nicotine spray (Nicorette
mouth spray 1mg/dose), which was granted for free by McNeil
AB, Sweden. The placebo spray was identical in appearance and
formulation, except for nicotine, which was replaced with cap-
saicin to mimic the taste of nicotine. The experimental design
consisted of three separate test sessions 2 to 7 days apart, ses-
sions in which participants received one of the three conditions
in a counterbalanced order. Fourteen neurocognitive tasks were
administered each testing day, distributed over three test blocks
of which the order was counterbalanced between participants and
experimental sessions. The results of the other cognitive tasks will
be reported separately. The duration of the different test blocks
was 45–60min and the interval between the test blocks lasted
150min. The participants received their dosage prior to each
test block (i.e., 30min before task onset), three times a day in
total. Smokers were not allowed to smoke 2h pre-dose. After each
test block smokers were allowed to smoke a maximum of three
cigarettes in a 15min period to prevent possible effect of nico-
tine withdrawal on the assessments. Blood samples were taken at
three time points relative to each administration (pre-dose, 5min
post-dose, and 1h post-dose, for mean values see Table 2).
TASK
The mini Ultimatum Game (mini-UG; Falk et al., 2003; Gürog˘lu
et al., 2009) was computerized and programmed in E-prime
version 2. In this version of the UG, a sum of money (C10)
is split in different distributions, named from the perspective
of the proposer: a fair one (5:5; 5 for the proposer, 5 for the
responder), a hyperfair one (2:8; 2 for the proposer, 8 for the
responder), an unfair distribution (8:2; 8 for the proposer, 2
for the responder), or a hyperunfair one (10:0; 10 for the pro-
poser, 0 for the responder). On each trial, the computer selects
two possible distributions (e.g., a hyperfair vs. an unfair dis-
trubtion: 2:8 vs. 8:2) of which the proposer has to choose one
(see Figure 1).
Next, the responder can accept or reject the proposed offer,
by pressing one of two buttons. If the responder accepts, both
players earn the amount of money as specified in the pro-
posal. Importantly, however, if the responder rejects, both players
receive nothing. All participants played the role of the respon-
der and were led to belief that the choices of the proposers were
based on behavioral data from subjects who had previously par-
ticipated as proposers. Furthermore, patients were instructed that
they played every round with a new proposer.
In total, 48 pairs of offers were presented by the computer
(12 unfair-fair, 12 unfair-hyperfair, 12 unfair-hyperunfair and 12
unfair-unfair). The software is programmed such that on 30 tri-
als (6 unfair-fair, 6 unfair-hyperfair, 6 unfair-hyperunfair and 12
FIGURE 1 | Display of the decision phase in the fair-alternative
condition of the modified UG. The left panel shows the name and
silhouette of the proposer at the top (here “Proposer”) as well as the name
of the participant underneath (here “You”). The two potential distributions
are specified by red and blue coins (red for the proposer, blue for the
responder; here 8:2 vs. 5:5). The selected offer is encircled in red. The
participant has to decide whether to accept (“Yes”) or reject (“No”) the
offer via button press.
Table 2 | Mean plasma concentration nicotine (ng/ml).
COHORTS Dose FIRST INTAKE SECOND INTAKE THIRD INTAKE
PREDOSE 5MIN 60MIN PREDOSE 5MIN 60MIN PREDOSE 5MIN 60MIN
Non smoking patients 0mg BQL BQL BQL BQL BQL BQL BQL BQL BQL
1mg BQL 1.9 (1.3) 1.4 (0.6) 1.0 (0.3) 3.5 (2.3) 2.4 (0.7) 1.3 (0.5) 3.3 (0.9) 2.4 (0.7)
2mg BQL 3.4 (2.8) 2.6 (1.3) 1.9 (0.7) 4.7 (1.8) 4.4 (1.5) 2.6 (0.8) 6.7 (2.9) 4.6 (1.5)
Smoking patients 0mg 12.6 (6.8) 11.7 (6.5) 8.4 (4.8) 15.7 (7.1) 13.1 (6.1) 9.8 (4.7) 15.3 (7.4) 13.2 (6.6) 9.6 (4.8)
1mg 11.6 (6.5) 11.6 (6.5) 8.9 (4.2) 13.4 (6.7) 13.1 (5.9) 10.3 (4.4) 12.9 (4.5) 13.7 (4.3) 10.4 (3.6)
2mg 11.8 (7.3) 12.5 (5.9) 10.2 (4.0) 15.3 (5.3) 16.0 (5.1) 12.7 (3.6) 14.9 (3.9) 16.7 (3.9) 14.3 (2.7)
Standard deviations are presented in parentheses.
BQL = Below Quantification Limit / Smokers: n = 15 / Non-smokers: n = 15 (2 mg) and n = 14 (1 mg and placebo).
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unfair-unfair) the proposer selects the unfair offer out of the two
available distributions. The unfair-unfair distribution is referred
to as the “no alternative” condition, as the proposer does not have
a real alternative choice. The primary outcome measure was the
rejection rates of the responder to the proposed unfair offers in
the four alternative conditions: alternative offer is (1) unfair, (2)
fair, (3) hyperfair, and (4) hyperunfair. The alternative conditions
are also referred to as the ‘context’. On the remaining 18 trials,
the proposer selects 6 fair, 6 hyperfair and 6 hyperunfair offers
instead of the unfair alternative. These data were not used in the
main analyses, but served as filler items.
This version of the UG has been constructed to investigate the
participants’ capability to make social decisions on the basis of
fairness and intentionality considerations in different contexts.
For example, higher rejection rates are expected when an unfair
offer is selected over a fair alternative, compared to when the
alternative was a hyperunfair offer. Also, lower rejection rates
are expected in the no alternative condition, when the proposer
has no other choice than choosing an unfair offer and thus not
treats the responder unfair in an intentional manner (see e.g.,
Gürog˘lu et al., 2009; Radke and de Bruijn, 2012; Radke et al.,
2012).
To strengthen the concept of an interactive game, it was
emphasized to participants that their decisions also affected the
other players’ outcome, because the eventual payoff of the pro-
posers would be determined by their response and proposers
would be paid after all data from the responders had been col-
lected. Furthermore, participants were informed that at the end
of the experiment a random number of rounds would be selected
to determine the payoff. This was done to ensure participants’
motivation and perception of a one-shot game, as every trial
could influence their financial outcome. The payoff was set at 10
euro over the three periods. The total duration of the task was
15–20min.
STATISTICAL ANALYSES
Analyses were run in SPSS Statistics version 20.0. Rejection
rates of unfair offers were entered into GLM repeated mea-
sures ANOVAs with Group (two level: smoking vs. non-smoking
patients) as between-subjects factor and Dose (three levels:
0mg vs. 1mg vs. 2mg) and Context (four levels: no-alternative
vs. fair vs. hyperfair vs. hyperunfair) as within-subject factors.
As analyses of the demographic variables revealed a signifi-
cant difference in age between the two groups (see Table 1),
age was entered as a covariate in the analyses. In accor-
dance with previous studies using the same paradigm (e.g.,
Gürog˘lu et al., 2009; Radke et al., 2012), a significance level
of 0.05 was applied for all analyses and significant inter-
actions were followed up by ANOVAs or two-tailed t-tests.
Greenhouse–Geisser corrections were applied when appropriate,
but uncorrected degrees of freedom values are given for ease
of interpretation.
RESULTS
OVERALL ANALYSES OF REJECTION RATES
Figure 2 depicts the rejection rates for the different offers (i.e.,
Context) for the two patient groups. As expected, a main effect of
Context was present [F(3, 26) = 3.05, p = 0.047], indicating that
rejection rates were dependent on the unchosen alternative offer.
Neither the main effect of Group [F(1, 28) = 1.47, p = 0.236],
nor the main effect of Dose was significant [F(2, 27) = 1.93, p =
0.165]. The interaction between Dose and Context [F(6, 23) =
2.60, p = 0.045] was significant. Neither the interaction between
Context and Group [F < 1], nor the interaction between Dose
and Group [F(2, 27) = 2.94, p = 0.070] was significant. None of
the interactions with the covariate age were significant [all Fs <
1.95, all ps> 0.146], except for the three-way interaction between
Dose, Context and Age [F(6, 23) = 3.38, p = 0.016]. Importantly,
the three-way interaction between Dose, Context, and Group was
significant [F(6, 23) = 3.45, p = 0.014]. The latter interaction was
further investigated by analyzing the two groups separately for
effects of Dose and Context.
Smoking schizophrenia patients
The main effect of Context was significant [F(3, 13) = 6.32, p =
0.007]. Neither the main effect of Dose [F(2, 14) = 2.95, p =
0.085], nor the interaction between Dose and Context was sig-
nificant [F < 1]. Follow-up contrasts for Context showed the
expected pattern, with increased rejections for fair (52.4%; p =
0.001) and hyperfair (50.7%; p = 0.008) alternatives compared to
the no-alternative condition (32.6%). The hyperunfair condition
(35.1%) did not differ from the no-alternative one (p = 0.473).
Non-smoking schizophrenia patients
For the non-smoking patient group, the main effect of Context
was not significant [F(3, 13) = 2.06, p = 0.16]. The main effect
of Dose was marginally significant [F(2, 14) = 3.54, p = 0.059].
Importantly, the interaction between Context and Dose was sig-
nificant [F(6, 10) = 4.07, p = 0.030]. This interaction was caused
by the finding that the non-smoking patients failed to show an
effect of Context in the placebo condition [F < 1]. They did
however show a main effect of Context after 1mg of nicotine
[F(3, 12) = 4.85, p = 0.015], but only a trend was seen after 2mg
of nicotine [F(3, 12) = 2.97, p = 0.074]. After 1mg of nicotine,
the expected pattern was found, with increased rejection rates
for fair alternatives (73.3%) compared to no-alternatives [51.6%;
p = 0.017]. The difference between the hyperfair (67.8%) and
no-alternative condition was marginally significant [p = 0.056]
and the hyperunfair (53.3%) alternative did not differ from the
no-alternative [p = 0.731].
DISCUSSION
The aim of the current study was to investigate the effects
of nicotine on social decision-making in smoking and non-
smoking schizophrenia patients. As demonstrated repeatedly in
healthy volunteers, the smoking patients’ decisions were affected
by the unchosen alternative offer in the expected pattern (see
e.g., Gürog˘lu et al., 2009; Radke and de Bruijn, 2012; Radke
et al., 2012). In other words, smoking patients incorporated
both fairness and intentionality considerations into their social
decision-making process. The non-smoking patients, however,
failed to take these considerations into account under placebo.
Interestingly, after administration of 1mg of nicotine, the non-
smoking patients also showed the similar decision pattern incor-
porating fairness and intentionality considerations. The smoking
patients’ responder behavior was not affected by nicotine.
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FIGURE 2 | Mean rejection rates in percentages for unfair offers depending on the alternative offers (context) for the two patient groups. Error bars
represent standard errors of the mean.
The current outcomes may be explained by impairments
in a mechanism that was recently put forward by Barch and
Ceaser (2012). The authors propose a common mechanism
driving the variety of deficits seen in schizophrenia, i.e., an
impaired ability to actively represent goal information in work-
ing memory to guide behavior. This so-called proactive control
heavily relies on dorsolateral prefrontal cortex (DLPFC) and
impairments in this brain area or connected areas may thus
importantly result in problems in this central function. DLPFC
dysfunctions have often been implicated in schizophrenia, for
example reduced activations in schizophrenia patients have been
repeatedly demonstrated during working memory tasks (see
e.g., Meyer-Lindenberg et al., 2005; Barch and Csernansky,
2007).
Importantly, proactive control is also central for adequate
social decision-making, as it requires maintaining a representa-
tion of the goal and integrating it in a complex context involving
elements of fairness and intentionality. For example, the uncho-
sen alternative offer has to remain active in working memory
to influence the final decision-making process (“What I have”
versus “What I could have had”). Also, one needs to take the
perspective of the other person into account in order to fully
understand if an unfair offer was made intentionally (fair alter-
native) or unintentionally (no alternative). This process requires
assessment of cognitive perspective taking and a recent develop-
mental study using this version of the UG has demonstrated that
typically developing children do not take alternative offers into
account until the age of 12 (Gürog˘lu et al., 2009). This finding
is in line with the protracted development of the involved brain
regions such as DLPFC (Crone and Dahl, 2012) and with the idea
that perspective taking is a function that develops slowly and well
into late adolescence (Dumontheil et al., 2010) and may thus be a
particularly vulnerable process in schizophrenia.
Although we are obviously careful in drawing conclusions
regarding neural mechanisms based on behavioral data alone,
fMRI studies using the UG have repeatedly demonstrated an
important role for DLPFC in response to unfair offers. The
area seems to play a central role in the implementation of fair-
ness motives when self-interests are competing (Sanfey et al.,
2003; Gürog˘lu et al., 2011). Also, disruption of DLPFC using
transcranial magnetic stimulation (TMS) resulted in increased
acceptance rates of unfair offers (van’t Wout et al., 2005; Knoch
et al., 2006), implicating that following TMS participants did
not implement their fairness goals in the social-decision-making
process.
The current findings may thus indicate that nicotine improves
proactive control in the non-smoking schizophrenia patients.
This interpretation is supported by neuroimaging findings that
reveal nicotine-induced activations in these tasks mainly in the
prefrontal cortex (for a recent review see Newhouse et al., 2011).
After administration of nicotine, non-smoking schizophrenia
patients may implement their fairness goals more in the decision-
making process, possibly through enhancement of DLPFC acti-
vation. Thus, in non-smoking patients with schizophrenia, a
deficient cholinergic system (see e.g., Leonard et al., 1998, 2007;
Mexal et al., 2010) in combination with diminished DLPFC activ-
ity (Meyer-Lindenberg et al., 2005; Barch and Csernansky, 2007)
may create the fundament for possible nicotine-induced stimu-
lation of proactive control (Barch and Ceaser, 2012). Obviously,
dedicated neuroimaging studies are needed to test the latter
hypothesis in the near future. Such studies would also shed
more light on whether improved proactive control results from
a direct influence on DLPFC or from a more indirect path-
way through facilitation of low-level processes. In support of the
latter interpretation, previous studies have demonstrated effects
of nicotine on processes required for proactive control, such as
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sustained attention (for a recent meta-analysis see Heishman
et al., 2010). Thus improved social decision-making in the cur-
rent paradigm may also result of more low-level enhancement
of attentional processes. For example, non-smoking patients may
attend more to the context after nicotine administration. This
may have an effect on the decisional value of the contextual dif-
ferences and may thus result in the currently found response
patterns. An interesting way to specifically investigate this issue
in the near future is by making use of eye-movement mea-
surements during performance of the UG. By doing so, one
could easily establish whether patients attend to the context in
the first place and whether this attention can be modulated by
nicotine administration.
Interestingly, the optimum in non-smoking patients is reached
after 1mg nicotine with a slight decline after 2mg, sug-
gestive for saturated nicotine concentrations in non-smoking
patients after 1mg oromucosal nicotine spray. These find-
ings are in line with a model of nicotinergic stimulation by
Newhouse et al. (2004), in which the authors propose the dose-
response curve to follow an inverted U shape (see e.g., Perkins
et al., 1994; Poltavski et al., 2012). This means that stimula-
tion by nicotine initially improves cognitive performance and
once the optimum is reached further stimulation is not effec-
tive or even detrimental. This interpretation is in line with
the idea that patients with schizophrenia are characterized by
hypocholinergic function and performance scores on the left
side of the dose-response curve, thus making room for cogni-
tive enhancement.
Smoking patients, on the other hand, did show integration
of context irrespective of dosage and were not able to improve
with nicotine. The most likely explanation is chronic saturation
with nicotine in smoking patients, placing themmore to the right
on the inverted U curve. This was supported by the high plasma
nicotine values at placebo and by the small additive effects of oro-
mucosal nicotine spray on the plasma levels. Note that this finding
is likely to be related to smoking patients being allowed to smoke
in between the test blocks to avoid unwanted effects of with-
drawal. Therefore, the current facilitating outcomes of nicotine
for the non-smoking patients only are in line withNewhouse et al.
(2011) who recently concluded that “nicotine appears to increase
task-related activity in non-smokers and deprived smokers, but
not active smokers.”
However, we would like to point out that based on the current
results we cannot exclude an alternative interpretation stating that
higher doses would have led to behavioral changes in this group.
Visual inspection of Figure 2, for example, may suggest more sim-
ilar response patterns after 2mg in the smoking patients and after
1mg of nicotine in the non-smoking group. This resemblance,
combined with the small additive effects of nicotine administra-
tion on plasma levels in the smoking patients, could thus suggest
that patients’ lack of improvement may be due to too low nico-
tine doses. It is important to note though, that the absolute
performance measures as reflected in these response patterns are
less relevant for the current study. Our main interest lies in the
presence of an effect of context, indicative of taking alternative
unselected offers into account. Therefore, the relative influence
of the different conditions rather than absolute rejection rates
is crucial for the studied processes of fairness and perspective
taking. Moreover, as smoking patients already show this distinc-
tion after placebo, it is not immediately evident how performance
could further improve.
We would like to emphasize that the current results war-
rant replication, especially given the relatively small sample size.
However, to our knowledge, this is the first study that investi-
gated the effects of nicotine on social cognition in schizophrenia
patients. Previous animal studies have repeatedly shown that
nicotine administration leads to oxytocin release in rats (see
e.g., Bisset and Walker, 1957; Russell and Chaudhury, 1972),
probably due to the effect nicotine has on the oxytocinergic
neurons in the hypothalamic paraventricular nuclei (Mikkelsen
et al., 2012). Over the past years, oxytocin has received a lot
of attention and a growing number of studies have revealed
a central role for the hormone in a variety of human social
cognitive processes, including social memory, emotion percep-
tion, empathy, and trust. Moreover, authors have also empha-
sized the possible potential of oxytocin for clinical populations
(for recent reviews see e.g., Guastella and MacLeod, 2012; Zink
and Meyer-Lindenberg, 2012; Bakermans-Kranenburg and van
IJzendoorn, 2013). In line with this, two recent studies have
demonstrated oxytocin-induced improvements in schizophre-
nia patients for social perception (Fischer-Shofty et al., 2013)
and for high-level social cognitive processes, such as deception
detection and empathy (Davis et al., 2013). However, translation
of these findings into therapeutic applications warrants further
investigation, especially since recent studies in healthy volun-
teers have also reported ‘antisocial’ rather than prosocial effects
(see e.g., De Dreu et al., 2010, 2011; Bartz et al., 2011; Radke
et al., 2012, 2013). The current findings thus importantly add
to the existing literature by showing that nicotine, known for
its cognitive enhancing role, may also facilitate central aspects
of social cognition necessary for efficient social behavior. An
interesting question for future studies remains whether or not
this nicotine-induced facilitation is mediated by the release of
oxytocin.
To conclude, the current study showed improved social
decision-making in non-smoking patients with schizophrenia
after administration of 1mg of nicotine. Although the present
study shows that nicotine may facilitate social cognitive pro-
cesses, it also suggests that the efficacy may be limited as the
effects were no longer present after a higher dose and did not
apply to the smoking patients. Thus, the possible clinical rel-
evance of these findings remain unclear and more research is
needed. For example, the effects of chronic nicotine adminis-
tration are unknown and it is difficult to predict how exactly
the currently found effects would translate to real-world set-
tings. However, the presently demonstrated acute effects may
make nicotine an interesting candidate as an adjunct to exist-
ing therapies, such as social-cognitive remediation. Future stud-
ies should investigate whether the efficacy of existing treatment
programs is improved by the nicotine-induced facilitation of
social decision-making processes. In short, the current find-
ings demonstrate that nicotine may facilitate social cognitive
processes through improved integration of different sources of
information and may thus especially be an interesting target
Frontiers in Neuroscience | Neuropharmacology October 2013 | Volume 7 | Article 197 | 6
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for cognitive enhancement in the subset of patients that do not
smoke.
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